Friday, 21 Sep 2018

You are here

Probenecid Benefits Heart Failure

In animal studies, probenecid was shown to have positive inotropic effects on the cardiomyocyte mediated by transient receptor potential vanilloid 2 activation. This concept was further studied in 20 patients with heart failure with reduced ejection fraction where probenecid was shown to improve cardiac function after just one week of probenecid treatment.

Probenecid is thought to exert its effects via calcium channel activation by transient receptor potential vanilloid 2.

Patients were treated in a randomized, double‐blind, crossover design. Clinical performance data were collected and parallel laboratory studies assessed murine cardiomyocytes exposed to probenecid or control treatments.

Probenecid therapy significantly increased fractional shortening by versus placebo (P=0.007) and improved diastolic function compared with placebo.

In vitro probenecid increased myofilament force generation (P<0.05) and calcium sensitivity (P<0.01) compared with control.

These findings suggest that myocardial benefits to probenecid treatment may be related to direct effects on calcium channel signaling rather than the indirect effects of serum urate on renal and vascular function. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

Usual Allopurinol Doses Insufficient in CKD Patients

Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.

Sleep Apnea Raises Gout Risk

Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.

In a large retrospective cohort study, the adjusted hazard ratio for a new gout diagnosis among individuals with sleep apnea was 1.42 (95% CI 1.29-1.56), according to Milica Blagojevic-Bucknall, PhD, of Keele University in Keele, England, and colleagues.

Adherence to Gout Therapies Painfully Low

A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.

Not All Hyperuricemia Leads to Gout

Dalbeth and colleagues studied 4 large prospective cohorts and found that rising levels of serum uric acid (SUA) leads to a non-linear increased risk of incident gout, but only half of those with SUA ≥10mg/dL developed clinically evident gout.